Patients with acute myocardial infarction are at a high risk of heart failure and death. Despite advances in care and reduction in the rate of recurrent myocardial infarctions, the risk for heart ...

The researchers found that the risk for first heart failure hospitalization and total heart failure hospitalizations was ...

MONDAY, April 8, 2024 (HealthDay News) -- For patients with acute myocardial infarction at risk for heart failure, empagliflozin reduces the risk for heart failure hospitalization, according to a ...

There are tablets for kids of every age, and content for every type of interest. Pretty much all devices come with parental controls, and it’s good to be wise to what your kids are accessing ...

Tablets have come a long way since Apple launched the iPad more than a decade ago. It wasn’t the first tablet on the market but it was – and remains – the most important. Its sleek design ...

The EMPACT-MI trial found that giving Boehringer Ingelheim and Eli Lilly’s SGLT2 drug Jardiance (empagliflozin) within 14 days of an acute myocardial infarction (AMI) reduced the risk of a ...

Empagliflozin was originally approved for use in patients with diabetes, but investigators chose to study the drug based on earlier findings that it showed benefit in preventing active heart ...

The researchers found that the risk for first heart failure hospitalization and total heart failure hospitalizations was significantly lower in the empagliflozin group versus the placebo group ...

These days, there are tablets for just about any pursuit you want one for. You can find a great tablet for watching movies as an alternative to a TV. Likewise, you can find a great tablet for ...

Empagliflozin improves cardiovascular outcomes in patients with heart failure, patients with type 2 diabetes who are at high cardiovascular risk, and patients with chronic kidney disease. The ...